November 6, 2019

Awny Farajallah, MD, FACP  
Vice President, Head US Medical  
Bristol-Myers Squibb Company  
3401 Princeton Pike  
Lawrence, NJ, 08648  
609-302-3927; awny.farajallah@bms.com

NCCN Guidelines® Panel: Cancer-Associated Venous Thromboembolic Disease Panel

Dear Panel Members,

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed clinical data for ELIQUIS® (apixaban) to the NCCN® Cancer-Associated Venous Thromboembolic Disease Panel for your consideration. This data has been published in the Journal of Thrombosis and Haemostasis on October 20, 2019. This study evaluated the safety of apixaban versus dalteparin for cancer associated venous thromboembolism.

FDA Approved Indications of ELIQUIS® (apixaban):
- To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.3
- For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.5
- For the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.3

Rationale: These data are being submitted in response to a standing request from NCCN® for new data.

As part of this submission, the following resources are included for your review.


Thank you for your consideration.

Sincerely,

Awny Farajallah, MD, FACP  
Vice President, Head US Medical  
Bristol-Myers Squibb Company